Clinical Trial Update: BRight DCB First-in-Human Study [NA]

View source ↗

Summary

This clinical trial update confirms the completion of the first-in-human study of Biotronik's BRight paclitaxel-coated balloon for peripheral artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• BRight DCB (paclitaxel-coated balloon)

Snippet

Sponsor: Biotronik CRC Inc. | Conditions: Peripheral Artery Disease | NA | Status: COMPLETED